Navigation Links
Controversial deal on public access of the human genome map

Celeron Genomics Inc, will soon publish its findings on the human genome project, which is a much talked about topic, considering that the mapping of the genes will enable one to have the information to manipulate individual characteristics like the color of the eye or even skin. It will also help say whether a cell will function normally or not, enabling one to screen babies in the womb for diseases, and device specific advancements against many hereditary diseases and remedies for crippling ailments.

While it is customary to make the results of such ground-breaking research available for unrestricted public access, Celeron Genomics Inc. has worked a controversial deal with leading journal Science which will store the entire resources in a public databank called ' Genbank', which will allow academic users to download a specific amount of information with no hang-up, but beyond which the academic must disclaim rights to use such information commercially. Commercial users will however have to pay for any information used. Researchers believe commercializing the information will heavily compromise scientific research.
'"/>




Page: 1

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Controversial Levis jean ad to be withdrawn
3. GMC Gives Controversial Fertility Doctor, A Clean Chit
4. Controversial Theory Says DNA Can Be Pushed To "Dark States"
5. Harvard Begins Controversial Human Stem Cell Cloning Project
6. Controversial Vaccine Raises Fury of the Church
7. The Controversial Stem Cell Transplant Surgery a Failure, Patient died
8. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
9. Ever-Controversial Mental Health Act To Be Decided Upon
10. UK public misled over downgrading cannabis: Govt
11. Czech Republic struck by fifth bird flu incident
Post Your Comments:
(Date:5/16/2008)...isease sufferers gain benefit from calcitriol, an ...News) -- Taking activated vitamin D may cut the ri...onic kidney disease by about one quarter, a new st...e than 1,400 patients, those being treated with ca... their overall risk of death lowered by 26 percent...
(Date:5/16/2008)...iser Seeks to Raise $38 Million for Life-threateni...ewswire/ -- Walkers in nearly,every state will rai...7 and,18 -- by participating in GREAT STRIDES, the...sis Foundation announced today., May is National ...s a,life-threatening genetic disease that causes f...
(Date:5/16/2008)...mine who would benefit most from chemo after surge...hDay News) -- A panel of 15 genes may help determi...lung cancer will experience a recurrence and, ther...tudy shows. , By extension, the same genetic s...essive forms of the cancer who would be able to fo...
(Date:5/16/2008)...ds Focus on Millions of Children Still in Danger, ...r UNICEF and The,Advertising Council today announc...s of national public service announcements (PSAs) ...r, Nicole Ritchie, Joel Madden, David,Duchovny, Te...vors of the,Myanmar cyclone. The Ad Council is dis...
Breaking Medicine News(10 mins):Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3
...rly 360 mobile teams have been pressed into servic...k the outbreak of water-borne and other seasonal d..."There was always a possibility of the outbreak of...because of the presence of moisture in the atmosph...
...hough weight lost can be lost in several ways, not... high-fiber whole grain cereal diet is one of the ... in the Journal of the American Dietetic Associati...ls not only help to lose weight but also gain some...
...revious survey of approximately 5,000 United Kingd...ercent of women reported habitual or regular snori... gender, obesity, excessive daytime sleepiness, in...and mechanical obstruction in the upper airway. Ad...
...ecent study in rats proposes that the highly malig...lows them to convert into highly mobile cells// , ...nvironment. According to the Duke Comprehensiv...g of the two alternating forms of tumor cells; tra...
Other Medicine News:Health News:Weight Loss Healthier with a Diet of Whole Grain Cereals 2Health News:Prevalence of Self-reported Snoring, Sleep-disordered Breathing in Military 2Health News:Cancer cell behavior during Metastasis – New finding 2Health News:Cancer cell behavior during Metastasis – New finding 3
(Date:5/16/2008)...rates Statistically Significant Reductions in Sele... - Abstract to be published in 2008 Proceedings of... Clinical Oncology, SAN DIEGO, May 16 /PRNewswire...x: ANX ) announced today that, in a registrationa...ted a statistically significant reduction,in gener...
(Date:5/15/2008)... N.J., May 15 /- Eisai Corporation of...6 clinical data abstracts about,compounds in the c...preclinical oncology research have been accepted f...American Society of Clinical Oncology (ASCO),taki... A wide variety of abstracts on Eisai marketed pro...
(Date:5/15/2008)...May 15 /- Medivation, Inc.,... ongoing Phase 1-2 clinical,trial of its novel and...ted,in an oral presentation at the 44th American S...in Chicago., Session title: New Targeted Strate...te and time: Monday, June 2 at 11:30 a.m. Central ...
(Date:5/15/2008)...acy Clinical Data from Prostate, Colorectal and Ov...Company to Hold Investor Event on Sun., June 1 wit..., May 15 /- Poniard,Pharmac...al company focused,on oncology, today announced th...al trials of picoplatin, in various tumor types an...
Breaking Medicine Technology:ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Precyse Solutions Appoints Karen Heisler as New Corporate Vice President Human Resources 16952 1Precyse Solutions Appoints Karen Heisler as New Corporate Vice President Human Resources 16952 221 Days to Creating Your Dream Life Will be Unleashed on April 28 2008 16949 121 Days to Creating Your Dream Life Will be Unleashed on April 28 2008 16949 2Anavex appoints Dr Dimitri Goundis to lead Clinical Development 4641 1Anavex appoints Dr Dimitri Goundis to lead Clinical Development 4641 2Anavex appoints Dr Dimitri Goundis to lead Clinical Development 4641 3Anavex appoints Dr Dimitri Goundis to lead Clinical Development 4641 4Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 1823 1Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 1823 2
... WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstC... and Medicine at Georgetown,University Medical Cen...es of Neurochem Inc.,s North American Phase III cl...present today an update on,Neurochem,s investigati...mer,s disease (AD). The presentation by Dr. Aisen ...
... ~ Valopicitabine achieved both primary and second...raction was observed between,valopicitabine and ri...wire-FirstCall/ -- Idenix,Pharmaceuticals, Inc. to...ed to evaluate triple combination therapy, consist...candidate for the,treatment of hepatitis C, pegyla...
Other Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6
...ected curve trial lenses are ground with the same ...nd are invaluable in treating low vision patients....rs contain a disproportionately large number of le... to produce, and fewer lenses in the higher power ...
simplified focusing guidance system has made the LM-770 the easiest instrument to use of its type. Technicians can be trained to operate the LM-770 with a minimum of instruction. The instrument tells
...on electronic refractor to its line of Vision Diag...ce of a wireless, infrared remote control and is p...s. The Evolution gives the practitioner complete c...eld remote control. With the Evolution, the practi...
Marco Radiusgauges are available with either a standard or digital display as well as in either monocular or binocular form. All offer the functions of two instruments in one, measuring both the curv
Medicine Products: